neuroblastoma shsy 5y cat crl 2266 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC neuroblastoma shsy 5y cat crl 2266 cells
    Neuroblastoma Shsy 5y Cat Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neuroblastoma shsy 5y cat crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    neuroblastoma shsy 5y cat crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars

    Images

    sh sy5y human neuroblastoma crl 2266 cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC sh sy5y human neuroblastoma crl 2266 cells
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Sh Sy5y Human Neuroblastoma Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sh sy5y human neuroblastoma crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sh sy5y human neuroblastoma crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars

    Images

    1) Product Images from "Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of mitochondria"

    Article Title: Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of mitochondria

    Journal: bioRxiv

    doi: 10.1101/2024.04.15.589474

    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of SH-SY5Y cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Figure Legend Snippet: ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of SH-SY5Y cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.

    Techniques Used: Activation Assay, Immunofluorescence, Staining, Western Blot, Stable Transfection, Expressing

    crl 2266  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2266
    Crl 2266, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 - by Bioz Stars, 2024-05
    86/100 stars

    Images

    atcc crl 2266  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC atcc crl 2266
    Atcc Crl 2266, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc crl 2266/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    atcc crl 2266 - by Bioz Stars, 2024-05
    86/100 stars

    Images

    crl 2266  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2266
    Crl 2266, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 - by Bioz Stars, 2024-05
    86/100 stars

    Images

    cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers
    Cell Lines Sh Sy5y Neuroblastoma Cell Atcc Crl 2266 Oligonucleotides Real Time Pcr Primers, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers - by Bioz Stars, 2024-05
    86/100 stars

    Images

    crl 2266 oligonucleotides  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2266 oligonucleotides
    Crl 2266 Oligonucleotides, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266 oligonucleotides/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 oligonucleotides - by Bioz Stars, 2024-05
    86/100 stars

    Images

    crl 2266 software  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2266 software
    Crl 2266 Software, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266 software/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 software - by Bioz Stars, 2024-05
    86/100 stars

    Images

    human sh sy5y crl 2266 cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC human sh sy5y crl 2266 cells
    CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in <t>SH-SY5Y</t> cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.
    Human Sh Sy5y Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human sh sy5y crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human sh sy5y crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars

    Images

    1) Product Images from "Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state"

    Article Title: Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state

    Journal: Disease Models & Mechanisms

    doi: 10.1242/dmm.049754

    CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in SH-SY5Y cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.
    Figure Legend Snippet: CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in SH-SY5Y cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.

    Techniques Used: Expressing, Standard Deviation, Two Tailed Test, RNA Sequencing Assay, Marker

    CD49b differentiates neuroblastoma cells with different signaling milieus. (A,B) GSEA enrichment plots showing enrichment of genes associated with the GSEA terms ‘PI3K-AKT signaling pathway’ (A) or ‘cytokine-cytokine receptor interaction’ (B) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. The green lines represent the running enrichment score and the red dashed lines denote the point of maximum enrichment within the ranked gene list. (C,D) Heatmaps showing enrichment of genes associated the GSEA terms ‘PI3K-AKT signaling pathway’ (C) or ‘cytokine-cytokine receptor interaction’ (D) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. (E,F) Quantification of flow cytometry analysis demonstrating increased p-Akt/p-AKT levels (E) and increased gp130 levels (F) in CD49b-expressing N2a (left) or SH-SY5Y (right) cells relative to CD49b-neg cells. Bars indicate mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -values.
    Figure Legend Snippet: CD49b differentiates neuroblastoma cells with different signaling milieus. (A,B) GSEA enrichment plots showing enrichment of genes associated with the GSEA terms ‘PI3K-AKT signaling pathway’ (A) or ‘cytokine-cytokine receptor interaction’ (B) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. The green lines represent the running enrichment score and the red dashed lines denote the point of maximum enrichment within the ranked gene list. (C,D) Heatmaps showing enrichment of genes associated the GSEA terms ‘PI3K-AKT signaling pathway’ (C) or ‘cytokine-cytokine receptor interaction’ (D) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. (E,F) Quantification of flow cytometry analysis demonstrating increased p-Akt/p-AKT levels (E) and increased gp130 levels (F) in CD49b-expressing N2a (left) or SH-SY5Y (right) cells relative to CD49b-neg cells. Bars indicate mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -values.

    Techniques Used: Flow Cytometry, Expressing, Standard Deviation, Two Tailed Test

    Neuroblastoma cells transition between CD49b expression profiles in culture. (A,C) Representative flow cytometry plots showing reanalysis of N2a cells (A) and SH-SY5Y cells (C) at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. APC, allophycocyanin channel; FSC, forward scatter. (B,D) Quantification of the proportion of N2a cells (B) and SH-SY5Y cells (D) in each CD49b expression category at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. (E) Dose response curve showing proportion of N2a cells surviving following 48 h of treatment with the indicated concentrations of doxorubicin, as measured by the CellTiter-Glo assay. (F) Proportion of total N2a cells within the CD49b-neg and CD49b-high gates after treatment with DMSO (vehicle) or 1 µM or 2 µM of doxorubicin for 48 h, as measured by flow cytometry. (G) Proportion of N2a cells that were CD49b-neg and CD49b-high at the conclusion of 48 h of treatment with 1 µM doxorubicin, and after 19 days of recovery in culture. Bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation.
    Figure Legend Snippet: Neuroblastoma cells transition between CD49b expression profiles in culture. (A,C) Representative flow cytometry plots showing reanalysis of N2a cells (A) and SH-SY5Y cells (C) at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. APC, allophycocyanin channel; FSC, forward scatter. (B,D) Quantification of the proportion of N2a cells (B) and SH-SY5Y cells (D) in each CD49b expression category at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. (E) Dose response curve showing proportion of N2a cells surviving following 48 h of treatment with the indicated concentrations of doxorubicin, as measured by the CellTiter-Glo assay. (F) Proportion of total N2a cells within the CD49b-neg and CD49b-high gates after treatment with DMSO (vehicle) or 1 µM or 2 µM of doxorubicin for 48 h, as measured by flow cytometry. (G) Proportion of N2a cells that were CD49b-neg and CD49b-high at the conclusion of 48 h of treatment with 1 µM doxorubicin, and after 19 days of recovery in culture. Bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation.

    Techniques Used: Expressing, Flow Cytometry, Glo Assay, Standard Deviation

    shsy5y crl 2266 cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC shsy5y crl 2266 cells
    Shsy5y Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shsy5y crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    shsy5y crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    ATCC neuroblastoma shsy 5y cat crl 2266 cells
    Neuroblastoma Shsy 5y Cat Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neuroblastoma shsy 5y cat crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    neuroblastoma shsy 5y cat crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC sh sy5y human neuroblastoma crl 2266 cells
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Sh Sy5y Human Neuroblastoma Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sh sy5y human neuroblastoma crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sh sy5y human neuroblastoma crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC crl 2266
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Crl 2266, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC atcc crl 2266
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Atcc Crl 2266, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc crl 2266/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    atcc crl 2266 - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Cell Lines Sh Sy5y Neuroblastoma Cell Atcc Crl 2266 Oligonucleotides Real Time Pcr Primers, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell lines sh sy5y neuroblastoma cell atcc crl 2266 oligonucleotides real time pcr primers - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC crl 2266 oligonucleotides
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Crl 2266 Oligonucleotides, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266 oligonucleotides/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 oligonucleotides - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC crl 2266 software
    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of <t>SH-SY5Y</t> cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.
    Crl 2266 Software, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2266 software/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2266 software - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC human sh sy5y crl 2266 cells
    CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in <t>SH-SY5Y</t> cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.
    Human Sh Sy5y Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human sh sy5y crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human sh sy5y crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    86
    ATCC shsy5y crl 2266 cells
    CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in <t>SH-SY5Y</t> cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.
    Shsy5y Crl 2266 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shsy5y crl 2266 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    shsy5y crl 2266 cells - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    Image Search Results


    ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of SH-SY5Y cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.

    Journal: bioRxiv

    Article Title: Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of mitochondria

    doi: 10.1101/2024.04.15.589474

    Figure Lengend Snippet: ULKRECs induce potent mitophagy after colocalisation and local activation of ULK1 at mitochondria (A) Representative immunofluorescence of PANC-1 cells treated with CCCP, ULKRECs or both and immunostained for TOM20 and ULK1 and counterstained with Alexa 488 and 568, respectively. Nuclei stained with Hoechst 33342. (B) Quantification of the colocalised ULK1 to TOM20 spot area of PANC-1 cells treated with DMSO, 5 μM CCCP, 10 μM BL-918, 10 μM BL-918 + 5 μM CCCP, 1 μM NZ-65, 1 μM NZ-65 + 5 μM CCCP, 1 μM NZ-66, 1 μM NZ-66 + 5 μM CCCP, 50 μM TSPO ligand, 1 μM NZ-65 + 50 μM TSPO ligand, 1 μM NZ-66 + 50 μM TSPO ligand. (C) Western blot of SH-SY5Y cells treated with 1 μM ULKRECs, 5 μM CCCP or both, probed for Mfn2, β-Actin and Tom20 – quantifications are shown in (D) for Mfn2, normalised to Actin, n = 5. (E) Representative images of SH-SY5Y cells stably expressing the mito-mKeima reporter treated with 3 μM CCCP, NZ-65 or both. Nuclei were stained with Hoechst 33342, healthy mitochondria are shown in green and mitochondria in lysosomes are shown in red. Fold change in mitophagy index over time after treatment for the indicated timepoints with title treatments alone or co-treated with 1.25 μM ULKREC or 10 μM ULKREC NZ-65 (F) or NZ-66 (G). Fold change in mitophagy index over time after treatment for the indicated timepoints with DMSO, 1.25 µM NZ-65 or NZ-66 ± 50 µM TSPO ligand under co-treatment with DMSO (H) or 3 µM CCCP (I). (J) Fold change in TMRM relative fluorescent intensity (and hence ΔΨ m ) after 1h treatment with DMSO, 3 μM CCCP or 20 μM ULKREC. Normalised to number of nuclei. All data shown are mean ± SD, n = 3, *p<0.05, **p<0.01, ***p<0.001. For colocalisation experiments one-way ANOVA with Šidák multiple comparisons test. For TMRM, One-way ANOVA with Dunnett’s multiple comparisons test. For western blots, one-way ANOVA with Tukey’s multiple comparisons test. For mito-mKeima experiments, Two-way ANOVA with Tukey’s multiple comparisons test.

    Article Snippet: HEK293T (human embryonic kidney) (CRL-3216), PANC-1 human pancreatic ductal adenocarcinoma (PDAC) (CRL-1496) and SH-SY5Y human neuroblastoma (CRL-2266) cells were purchased from ATCC.

    Techniques: Activation Assay, Immunofluorescence, Staining, Western Blot, Stable Transfection, Expressing

    CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in SH-SY5Y cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.

    Journal: Disease Models & Mechanisms

    Article Title: Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state

    doi: 10.1242/dmm.049754

    Figure Lengend Snippet: CD49b expression distinguishes transcriptionally disparate subpopulations within neuroblastoma cell lines. (A) qPCR for the indicated genes in N2a cells sorted into CD49b-neg and CD49b-high fractions. Gapdh expression was used for normalization. (B) qPCR for the indicated genes in SH-SY5Y cells sorted into CD49b-neg and CD49b-pos fractions. GAPDH expression was used for normalization. For A,B, bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -value. (C) Volcano plot showing differentially expressed genes in CD49b-neg N2a cells relative to CD49b-high N2a cells identified by poly(A)-enriched RNA sequencing. 4251 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. (D) Volcano plot showing differentially expressed genes in CD49b-neg SH-SY5Y cells relative to CD49b-pos SH-SY5Y cells identified by poly(A)-enriched RNA sequencing. 8409 genes had |log 2 (fold change or FC)|>1 and P -value <0.001. NS, not significant. (E) Heatmap showing enrichment of selected neuronal marker genes in CD49b-high N2a cells relative to CD49b-neg N2a cells. (F) Heatmap showing enrichment of selected neuronal marker genes in CD49b-pos SH-SY5Y cells relative to CD49b-neg SH-SY5Y cells. For E,F, heatmaps reflect z-scores of log 2 -scale differences in gene expression. (G) Dot plot showing the proportion of cells expressing the indicated neuronal marker genes, stratified by cell cycle status inferred from gene expression patterns (data from GSE137804 ; ). Dot size indicates the proportion of cells expressing each gene, and color indicates the relative level of expression. (H) Proliferation in culture of SH-SY5Y cells sorted into CD49b-pos and CD49b-neg fractions ( n =5). Two-tailed unpaired t -tests were used to calculate P -values.

    Article Snippet: Mouse 3T3 Swiss (CCL-92), mouse N2a (CCL-131) and human SH-SY5Y (CRL-2266) cells without mycoplasma detection were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Expressing, Standard Deviation, Two Tailed Test, RNA Sequencing Assay, Marker

    CD49b differentiates neuroblastoma cells with different signaling milieus. (A,B) GSEA enrichment plots showing enrichment of genes associated with the GSEA terms ‘PI3K-AKT signaling pathway’ (A) or ‘cytokine-cytokine receptor interaction’ (B) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. The green lines represent the running enrichment score and the red dashed lines denote the point of maximum enrichment within the ranked gene list. (C,D) Heatmaps showing enrichment of genes associated the GSEA terms ‘PI3K-AKT signaling pathway’ (C) or ‘cytokine-cytokine receptor interaction’ (D) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. (E,F) Quantification of flow cytometry analysis demonstrating increased p-Akt/p-AKT levels (E) and increased gp130 levels (F) in CD49b-expressing N2a (left) or SH-SY5Y (right) cells relative to CD49b-neg cells. Bars indicate mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -values.

    Journal: Disease Models & Mechanisms

    Article Title: Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state

    doi: 10.1242/dmm.049754

    Figure Lengend Snippet: CD49b differentiates neuroblastoma cells with different signaling milieus. (A,B) GSEA enrichment plots showing enrichment of genes associated with the GSEA terms ‘PI3K-AKT signaling pathway’ (A) or ‘cytokine-cytokine receptor interaction’ (B) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. The green lines represent the running enrichment score and the red dashed lines denote the point of maximum enrichment within the ranked gene list. (C,D) Heatmaps showing enrichment of genes associated the GSEA terms ‘PI3K-AKT signaling pathway’ (C) or ‘cytokine-cytokine receptor interaction’ (D) in CD49b-high N2a (left) or CD49b-pos SH-SY5Y (right) cells relative to CD49b-neg cells. (E,F) Quantification of flow cytometry analysis demonstrating increased p-Akt/p-AKT levels (E) and increased gp130 levels (F) in CD49b-expressing N2a (left) or SH-SY5Y (right) cells relative to CD49b-neg cells. Bars indicate mean, dots indicate individual replicates, and error bars indicate standard deviation. Two-tailed unpaired t -tests were used to calculate P -values.

    Article Snippet: Mouse 3T3 Swiss (CCL-92), mouse N2a (CCL-131) and human SH-SY5Y (CRL-2266) cells without mycoplasma detection were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Flow Cytometry, Expressing, Standard Deviation, Two Tailed Test

    Neuroblastoma cells transition between CD49b expression profiles in culture. (A,C) Representative flow cytometry plots showing reanalysis of N2a cells (A) and SH-SY5Y cells (C) at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. APC, allophycocyanin channel; FSC, forward scatter. (B,D) Quantification of the proportion of N2a cells (B) and SH-SY5Y cells (D) in each CD49b expression category at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. (E) Dose response curve showing proportion of N2a cells surviving following 48 h of treatment with the indicated concentrations of doxorubicin, as measured by the CellTiter-Glo assay. (F) Proportion of total N2a cells within the CD49b-neg and CD49b-high gates after treatment with DMSO (vehicle) or 1 µM or 2 µM of doxorubicin for 48 h, as measured by flow cytometry. (G) Proportion of N2a cells that were CD49b-neg and CD49b-high at the conclusion of 48 h of treatment with 1 µM doxorubicin, and after 19 days of recovery in culture. Bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation.

    Journal: Disease Models & Mechanisms

    Article Title: Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state

    doi: 10.1242/dmm.049754

    Figure Lengend Snippet: Neuroblastoma cells transition between CD49b expression profiles in culture. (A,C) Representative flow cytometry plots showing reanalysis of N2a cells (A) and SH-SY5Y cells (C) at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. APC, allophycocyanin channel; FSC, forward scatter. (B,D) Quantification of the proportion of N2a cells (B) and SH-SY5Y cells (D) in each CD49b expression category at 7 and 21 days, respectively, after cultures were initiated with the indicated starting populations. (E) Dose response curve showing proportion of N2a cells surviving following 48 h of treatment with the indicated concentrations of doxorubicin, as measured by the CellTiter-Glo assay. (F) Proportion of total N2a cells within the CD49b-neg and CD49b-high gates after treatment with DMSO (vehicle) or 1 µM or 2 µM of doxorubicin for 48 h, as measured by flow cytometry. (G) Proportion of N2a cells that were CD49b-neg and CD49b-high at the conclusion of 48 h of treatment with 1 µM doxorubicin, and after 19 days of recovery in culture. Bars indicate the mean, dots indicate individual replicates, and error bars indicate standard deviation.

    Article Snippet: Mouse 3T3 Swiss (CCL-92), mouse N2a (CCL-131) and human SH-SY5Y (CRL-2266) cells without mycoplasma detection were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Expressing, Flow Cytometry, Glo Assay, Standard Deviation